Journal article
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery
Abstract
Background: There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. This analysis was performed to characterize the population pharmacokinetics and pharmacodynamics of rivaroxaban in patients participating in two phase II, double-blind, randomized, …
Authors
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK
Journal
Clinical Pharmacokinetics, Vol. 47, No. 3, pp. 203–216
Publisher
Springer Nature
Publication Date
March 2008
DOI
10.2165/00003088-200847030-00006
ISSN
0312-5963
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAge FactorsAgedAged, 80 and overArthroplasty, Replacement, HipArthroplasty, Replacement, KneeDose-Response Relationship, DrugDouble-Blind MethodFactor Xa InhibitorsFemaleHumansMaleMiddle AgedModels, BiologicalMorpholinesNonlinear DynamicsProthrombin TimeRivaroxabanSex FactorsThiophenesTime FactorsTissue DistributionVenous Thromboembolism